With 1.93 million new global cases and 935,000 deaths recorded in 2020, colorectal cancer leaves behind a dataset too urgent to ignore, and this post breaks down the numbers, trends, risk factors, screening guidance, and treatment outcomes shaping what comes next.
Key Takeaways
- 1.93 million new cases of colorectal cancer were diagnosed globally in 2020
- 935,000 deaths due to colorectal cancer occurred globally in 2020
- 10.0% of all cancer cases globally were colorectal cancer in 2020
- Colorectal cancer screening tests can detect precancerous polyps and early cancers, with adenoma detection affecting risk reduction outcomes (systematic evidence basis)
- A meta-analysis reported that processed meat consumption is associated with an increased colorectal cancer risk (summary relative risk)
- Physical activity is associated with reduced colorectal cancer risk; a dose-response meta-analysis found risk reduction with higher activity levels
- The U.S. Preventive Services Task Force recommends colorectal cancer screening for adults aged 45 to 75 years with Grade A/strong recommendation (screening eligible group definition)
- USPSTF recommends selective screening for adults aged 76 to 85 years (Grade C recommendation)
- In the United States, fecal immunochemical testing (FIT) can be used for colorectal cancer screening on an annual basis (screening interval guideline)
- Microsatellite instability-high (MSI-H) occurs in about 15% of colorectal cancers (molecular subgroup prevalence estimate)
- For metastatic MSI-H/dMMR colorectal cancer, pembrolizumab has an objective response rate of 33% (KEYNOTE-016/KEYNOTE-164 pooled evidence)
- Nivolumab plus ipilimumab produced an objective response rate of 55% in a cohort of MSI-H/dMMR colorectal cancer patients (CheckMate 142 result)
In 2020, colorectal cancer caused 1.93 million cases and 935,000 deaths worldwide.
Disease Burden
11.93 million new cases of colorectal cancer were diagnosed globally in 2020[1]
Verified2935,000 deaths due to colorectal cancer occurred globally in 2020[1]
Verified310.0% of all cancer cases globally were colorectal cancer in 2020[1]
Verified49.4% of all cancer deaths globally were colorectal cancer in 2020[1]
Directional5151,030 estimated new colorectal cancer cases were diagnosed in the United States in 2024[2]
Single source652,550 estimated colorectal cancer deaths occurred in the United States in 2024[2]
Verified767,680 estimated new cases of colon cancer occurred in the United States in 2024[2]
Verified816,500 estimated new cases of rectal cancer occurred in the United States in 2024[2]
Verified929,550 estimated colon cancer deaths occurred in the United States in 2024[2]
Directional105,930 estimated rectal cancer deaths occurred in the United States in 2024[2]
Single source11The age-standardized incidence rate of colorectal cancer is 19.3 per 100,000 in men globally (2020)[1]
Verified12The age-standardized incidence rate of colorectal cancer is 14.9 per 100,000 in women globally (2020)[1]
Verified13The age-standardized mortality rate of colorectal cancer is 10.7 per 100,000 in men globally (2020)[1]
Verified14The age-standardized mortality rate of colorectal cancer is 7.7 per 100,000 in women globally (2020)[1]
Directional151 in 7 colorectal cancer cases occur in people younger than 50 in the United States (estimated)[3]
Single source16The proportion of colorectal cancer diagnoses among adults aged 50 or older is 91% in the United States (estimated)[3]
VerifiedDisease Burden Interpretation
In 2020, colorectal cancer accounted for 10.0% of all global cancer cases and 9.4% of cancer deaths, and in the United States alone an estimated 151,030 new cases and 52,550 deaths are expected in 2024, showing a large burden that remains substantial even in high-income settings.
Epidemiology & Risk
1Colorectal cancer screening tests can detect precancerous polyps and early cancers, with adenoma detection affecting risk reduction outcomes (systematic evidence basis)[4]
Verified2A meta-analysis reported that processed meat consumption is associated with an increased colorectal cancer risk (summary relative risk)[5]
Verified3Physical activity is associated with reduced colorectal cancer risk; a dose-response meta-analysis found risk reduction with higher activity levels[6]
Verified4Alcohol consumption is associated with increased colorectal cancer risk in a meta-analysis (pooled effect estimate)[7]
Directional5Obesity is associated with increased colorectal cancer risk; meta-analysis estimates demonstrate a higher risk for obese individuals[8]
Single source6Diabetes is associated with increased colorectal cancer risk; pooled analysis indicates higher risk among people with diabetes[9]
Verified7Lynch syndrome accounts for about 2%–4% of colorectal cancer cases (genetic condition contribution estimate)[10]
Verified8Familial adenomatous polyposis (FAP) accounts for about 1% of colorectal cancer cases (genetic condition contribution estimate)[11]
Verified9Individuals with Lynch syndrome have a colorectal cancer lifetime risk of up to 20%–44% (depending on gene and sex)[10]
Directional10Individuals with Lynch syndrome have a lifetime endometrial cancer risk of up to 40%–60% (context for hereditary cancer syndrome burden)[10]
Single source11Individuals with FAP have virtually 100% risk of developing colorectal cancer without prophylactic surgery[11]
Verified12Estimated prevalence of colorectal cancer in patients with inflammatory bowel disease is higher than the general population, with cumulative risk rising with duration (IBD risk summary)[12]
Verified13Chronic ulcerative colitis cumulative colorectal cancer risk approaches about 2% after 10 years of disease (population-based summary)[12]
Verified14Chronic ulcerative colitis cumulative colorectal cancer risk may reach about 8% by 20 years (population-based summary)[12]
DirectionalEpidemiology & Risk Interpretation
Across these findings, lifestyle and metabolic factors drive higher colorectal cancer risk while genetics and chronic bowel disease add substantial but smaller proportions, notably that Lynch syndrome confers a colorectal lifetime risk up to 20%–44% and ulcerative colitis cumulative risk climbs to about 2% after 10 years and up to about 8% by 20 years.
Screening & Detection
1The U.S. Preventive Services Task Force recommends colorectal cancer screening for adults aged 45 to 75 years with Grade A/strong recommendation (screening eligible group definition)[13]
Verified2USPSTF recommends selective screening for adults aged 76 to 85 years (Grade C recommendation)[13]
Verified3In the United States, fecal immunochemical testing (FIT) can be used for colorectal cancer screening on an annual basis (screening interval guideline)[13]
Verified4In the United States, FIT-DNA testing is recommended every 1 to 3 years depending on test brand (screening interval guideline)[13]
Directional5In the United States, stool-based tests are recommended at intervals; colonoscopy is recommended every 10 years if normal (screening interval guideline)[13]
Single source6The average risk colorectal cancer screening starting age was lowered to 45 years in USPSTF 2021 recommendations[13]
Verified7FIT detects colorectal cancer with higher sensitivity than older guaiac-based tests (comparative performance summarized in USPSTF evidence)[14]
Verified8Colonoscopy is widely used as a primary screening option with an interval of 10 years after a normal examination (guideline standard)[14]
Verified9CT colonography is an option used at 5-year intervals after a normal examination in many guideline summaries (screening interval)[14]
Directional10In randomized evidence, CRC screening with fecal occult blood testing reduces colorectal cancer mortality (mortality reduction stated in major trials synthesis)[15]
Single source11In a large trial, flexible sigmoidoscopy screening reduced colorectal cancer incidence during follow-up (trial-reported effect)[16]
Verified12In a European randomized trial, screening colonoscopy versus no screening was associated with reduced CRC incidence during follow-up (trial evidence)[17]
Verified13In the United States, the USPSTF recommends offering screening using stool-based tests or visual inspection tests rather than blood-based tests (screening strategy recommendation)[14]
VerifiedScreening & Detection Interpretation
The USPSTF’s 2021 shift to start average-risk colorectal cancer screening at age 45, with annual FIT or FIT-DNA every 1 to 3 years, shows a clear move toward earlier and more frequent stool-based detection, while benefits from multiple trials and longer-interval colonoscopy still support screening to reduce colorectal cancer incidence and mortality.
Treatment & Outcomes
1Microsatellite instability-high (MSI-H) occurs in about 15% of colorectal cancers (molecular subgroup prevalence estimate)[18]
Verified2For metastatic MSI-H/dMMR colorectal cancer, pembrolizumab has an objective response rate of 33% (KEYNOTE-016/KEYNOTE-164 pooled evidence)[19]
Verified3Nivolumab plus ipilimumab produced an objective response rate of 55% in a cohort of MSI-H/dMMR colorectal cancer patients (CheckMate 142 result)[20]
Verified4In CheckMate 142, the median progression-free survival for MSI-H/dMMR colorectal cancer with nivolumab plus ipilimumab was 8.9 months (reported result)[20]
Directional5In CheckMate 142, the median duration of response for MSI-H/dMMR colorectal cancer was 18.9 months (reported result)[20]
Single source6In BEACON CRC, targeted therapy with encorafenib plus cetuximab achieved an overall response rate of 26% in BRAF V600E metastatic colorectal cancer (trial result)[21]
Verified7In BEACON CRC, median overall survival with encorafenib plus cetuximab was 9.3 months (trial result)[21]
Verified8In BEACON CRC, median progression-free survival with encorafenib plus cetuximab was 4.4 months (trial result)[21]
Verified9In KRAS/NRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy, response rates depend on trial regimen, with typical objective response rates reported in the 30% range (evidence summary)[22]
Directional10In metastatic colorectal cancer, first-line FOLFOX plus bevacizumab yielded an objective response rate of 45% in the pivotal AVF2107g trial (reported result)[23]
Single source11In AVF2107g, median overall survival with bevacizumab plus chemotherapy was 20.3 months (reported result)[23]
Verified12In AVF2107g, median progression-free survival with bevacizumab plus chemotherapy was 9.2 months (reported result)[23]
Verified13For metastatic colorectal cancer, adding bevacizumab to chemotherapy improves overall survival compared with chemotherapy alone (benefit quantified in trial)[24]
Verified14In a trial (IMPACT) for metastatic colorectal cancer, overall response rate with FOLFIRI plus cetuximab in KRAS wild-type tumors was 39% (reported result)[25]
Directional15In FIRE-3, cetuximab plus FOLFIRI after progression yielded a median overall survival of 28.3 months in certain KRAS wild-type analyses (trial report values)[26]
Single source16For metastatic disease, the median survival is about 30 months for well-selected patients receiving modern systemic therapy (summary of trial era outcomes)[27]
Verified17In early-stage colon cancer, adjuvant chemotherapy can improve survival by reducing recurrence risk (effect quantified in meta-analyses)[28]
Verified18In stage III colon cancer, adjuvant chemotherapy (5-FU-based regimens) has been shown to improve 5-year overall survival by about 10% in meta-analyses[29]
Verified19Neoadjuvant chemoradiation for locally advanced rectal cancer enables sphincter preservation in a substantial fraction of patients; trials report around 70% of patients receiving total mesorectal excision achieve sphincter preservation (reported range)[30]
Directional20A pathologic complete response rate around 20% is reported for selected rectal cancer patients treated with neoadjuvant chemoradiotherapy regimens (trial evidence summaries)[31]
Single source21In the PRODIGE 23 trial, adjuvant modified FOLFOX6 was compared with observation; 5-year disease-free survival improved (quantified benefit)[32]
Verified22In a large analysis, MSI-H/dMMR colorectal cancers have better prognosis and response to immunotherapy compared with MSS tumors (quantified in survival outcomes summaries)[33]
Verified23The overall response rate to immunotherapy is higher in MSI-H/dMMR colorectal cancer than in MSS colorectal cancer (pooled evidence)[34]
Verified24In CHECKMATE 142, the 1-year overall survival rate for nivolumab plus ipilimumab in MSI-H/dMMR colorectal cancer was 82% (reported)[20]
Directional25In KEYNOTE-016/164/158 evidence, pembrolizumab 1-year overall survival for MSI-H/dMMR colorectal cancer was reported above 70% (trial reporting)[19]
Single sourceTreatment & Outcomes Interpretation
Across colorectal cancer subtypes, immunotherapy stands out for MSI-H/dMMR disease with pembrolizumab delivering a 33% response rate and nivolumab plus ipilimumab reaching 55%, while even without cure many patients experience durable benefit with median progression-free survival of 8.9 months and median duration of response of 18.9 months.
References
- 1gco.iarc.fr/today/factsheets/cancers/10_Colorectal_factsheet.pdf
- 2acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21820
- 3acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21410
- 4jamanetwork.com/journals/jama/fullarticle/2755120
- 13jamanetwork.com/journals/jama/fullarticle/2813021
- 5pubmed.ncbi.nlm.nih.gov/29452063/
- 6pubmed.ncbi.nlm.nih.gov/26808259/
- 7pubmed.ncbi.nlm.nih.gov/26083176/
- 8pubmed.ncbi.nlm.nih.gov/25904348/
- 9pubmed.ncbi.nlm.nih.gov/28813853/
- 22pubmed.ncbi.nlm.nih.gov/31619965/
- 28pubmed.ncbi.nlm.nih.gov/18305409/
- 29pubmed.ncbi.nlm.nih.gov/20160843/
- 30pubmed.ncbi.nlm.nih.gov/23939974/
- 10ncbi.nlm.nih.gov/books/NBK1252/
- 11ncbi.nlm.nih.gov/books/NBK1282/
- 12ncbi.nlm.nih.gov/pmc/articles/PMC3207147/
- 17ncbi.nlm.nih.gov/pmc/articles/PMC7012938/
- 18ncbi.nlm.nih.gov/books/NBK534967/
- 27ncbi.nlm.nih.gov/books/NBK361177/
- 31ncbi.nlm.nih.gov/pmc/articles/PMC6333710/
- 33ncbi.nlm.nih.gov/pmc/articles/PMC8354217/
- 14uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
- 15nejm.org/doi/full/10.1056/NEJMoa1215877
- 16nejm.org/doi/full/10.1056/NEJMoa0813041
- 19nejm.org/doi/full/10.1056/NEJMoa1910549
- 20nejm.org/doi/full/10.1056/NEJMoa1910751
- 21nejm.org/doi/full/10.1056/NEJMoa1904039
- 23nejm.org/doi/full/10.1056/NEJMoa061822
- 24nejm.org/doi/full/10.1056/NEJMoa0707695
- 25nejm.org/doi/full/10.1056/NEJMoa0708426
- 26nejm.org/doi/full/10.1056/NEJMoa1215073
- 32nejm.org/doi/full/10.1056/NEJMoa1903043
- 34nejm.org/doi/full/10.1056/NEJMoa2024462